Novartis receives approval in EU for Xolair to treat children age 6 to 11 years suffering from severe persistent allergic asthma

Novartis announced today that the European Commission (EC) has approved Xolair® (omalizumab) as add-on therapy for severe persistent allergic asthma in children age 6 to 11 years.

The details can be read here.